Tango Therapeutics, Inc. (TNGX) Stock Jumps 16.3%: Will It Continue to Soar?Zacks Investment Research • 10/18/22
Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual MeetingGlobeNewsWire • 10/05/22
Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Can Tango Therapeutics, Inc. (TNGX) Climb 219% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/15/22
Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/10/22
Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/11/22
Wall Street Analysts Predict a 176% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should KnowZacks Investment Research • 04/22/22
Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/28/22
Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual MeetingGlobeNewsWire • 03/08/22
Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies CongressGlobeNewsWire • 03/03/22
Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress UpdatesGlobeNewsWire • 01/24/22
Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/09/21
Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General CounselGlobeNewsWire • 11/01/21
Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021Business Wire • 09/30/21